Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...

This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...

When I encounter a newly diagnosed EGFR mutation lung cancer ... Because although chemo is a old type of drug, but it still works, especially with the new data. When chemo is combined with ...

Previously, EGFR mutation-positive NSCLC patients relied ... Both trials linked the drug's chemo combo to longer life expectancy and progression-free survival time compared with chemo alone.

PACC mutation is around the 12% of all EGFR. So there are newer drug development specifically aiming for those space, including exon 20. We have amivantamab approved in combination with chemo in ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

in which treatment with the drug after surgery reduced the relative risk of disease recurrence or death by 83% compared to placebo in patients with stage 2 to 3A EGFR-mutated NSCLC. Survival without ...